This article explores strategies for formulating complex and emerging biologics, the role of predictive modeling, and ...
In December 2025, FDA announced that it was deploying agentic AI capabilities across the agency. FDA defined these systems as ...
In part 2 of his overview on hold times in biopharmaceuticals, Robert Dream details the regulations that govern hold times ...
FDA approves Rasonque (daraxonrasib), the first broad RAS-targeted therapy for metastatic pancreatic cancer, validating RAS ...
Continuous direct compression can provide a simplified alternative pathway for selected spray-dried dispersion formulations ...
As 3D printers become more accessible and easier to use, researchers are finding new ways to incorporate this technology into their work. 1 3D bioprinters utilizing natural, synthetic, and hybrid ...
Centrix and University of Sussex launch a data analytics partnership to reduce development risk, rework and delays in early-stage pharma programs. A collaboration between Centrix Pharma Solutions, a ...
McKesson plans to absorb Precision Medicine Group into Oncology & Multispecialty, adding CRO, lab, biomarker, market access, and commercialization capabilities to its existing healthcare services ...
David S. Thompson, CSAP, is Chief Alliance Officer at Eli Lilly and Company.
On August 19,2026, the FDA accepted Teva Pharmaceuticals' New Drug Application (NDA) for ecopipam, an investigational ...
FDA priority review of Jemperli for biomarker-defined rectal cancer signals capacity, supply chain, and global filing shifts ...
Results that may be inaccessible to you are currently showing.
Hide inaccessible results